• 1
    Faco MM, Leone C, Campos LM, Febronio MV, Marques HH, Silva CA.Risk factors associated with the death of patients hospitalized for juvenile systemic lupus erythematosus. Braz J Med Biol Res2007;40:9931002.
  • 2
    Carneiro-Sampaio M, Liphaus BL, Jesus AA, Silva CA, Oliveira JB, Kiss MH.Understanding systemic lupus erythematosus physiopathology in the light of primary immunodeficiencies. J Clin Immunol2008;28 Suppl:S3441.
  • 3
    Sachedina N, Donaldson LJ.Paediatric mortality related to pandemic influenza A H1N1 infection in England: an observational population-based study. Lancet2010;376:184652.
  • 4
    Silva CA, Terreri MT, Aikawa NE, Carvalho JF, Pileggi GC, Ferriani VP, et al.Vaccination practice in children with rheumatic disease. Rev Bras Reumatol2010;50:35161.
  • 5
    Heijstek MW, Ott de Bruin LM, Bijl M, Borrow R, van der Klis F, Kone-Paut I, et al.EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis2011;70:170412.
  • 6
    Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, et al, and the Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010 [published errata appear in MMWR Recomm Rep 2010;59:993 and in MMWR Recomm Rep 2010;59:1147]. MMWR Recomm Rep2010;59:162.
  • 7
    Kanakoudi-Tsakalidou F, Trachana M, Pratsidou-Gertsi P, Tsitsami E, Kyriazopoulou-Dalaina V.Influenza vaccination in children with chronic rheumatic diseases and long-term immunosuppressive therapy. Clin Exp Rheumatol2001;19:58994.
  • 8
    Ogimi C, Tanaka R, Saitoh A, Oh-Ishi T.Immunogenicity of influenza vaccine in children with pediatric rheumatic diseases receiving immunosuppressive agents. Pediatr Infect Dis J2011;30:20811.
  • 9
    Aikawa NE, Campos LM, Silva CA, Carvalho JF, Saad CG, Trudes G, et al.Glucocorticoid: major factor for reduced immunogenicity of 2009 influenza A (H1N1) vaccine in patients with juvenile autoimmune rheumatic disease. J Rheumatol2012;39:16773.
  • 10
    Abu-Shakra M.Safety of vaccination of patients with systemic lupus erythematosus. Lupus2009;18:12058.
  • 11
    Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum1997;40:1725.
  • 12
    Gladman DD, Ibanez D, Urowitz MB.Systemic Lupus Erythematosus Disease Activity Index 2000. J Rheumatol2002;29:28891.
  • 13
    Precioso AR, Miraglia JL, Campos LM, Goulart AC, Timenetsky Mdo C, Cardoso MR, et al.A phase I randomized, double-blind, controlled trial of 2009 influenza A (H1N1) inactivated monovalent vaccines with different adjuvant systems. Vaccine2011;29:897481.
  • 14
    Kendal AP, Pereira MS, Skehel JJ.Concepts and procedures from laboratory-based influenza surveillance. Atlanta: Centers for Disease Control and Prevention; 1982.
  • 15
    Oh CE, Lee J, Kang JH, Hong YJ, Kim YK, Cheong HJ, et al.Safety and immunogenicity of an inactivated split-virus influenza A/H1N1 vaccine in healthy children from 6 months to <18 years of age: a prospective, open-label, multi-center trial. Vaccine2010;28:585763.
  • 16
    Lu CY, Shao PL, Chang LY, Huang YC, Chiu CH, Hsieh YC, et al.Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A (H1N1) in children and adolescents. Vaccine2010;28:586470.
  • 17
    Liang XF, Wang HQ, Wang JZ, Fang HH, Wu J, Zhu FC, et al.Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet2010;375:5666.
  • 18
    Rimmelzwaan GF, Nieuwkoop N, Brandenburg A, Sutter G, Beyer WE, Maher D, et al.A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines. Vaccine2000;19:11807.
  • 19
    Conti F, Rezai S, Valesini G.Vaccination and autoimmune rheumatic diseases. Autoimmun Rev2008;8:1248.
  • 20
    Bate J, Yung CF, Hoschler K, Sheasby L, Morden J, Taj M, et al.Immunogenicity of pandemic (H1N1) 2009 vaccine in children with cancer in the United Kingdom. Clin Infect Dis2010;51:e95104.
  • 21
    Crowe SR, Merrill JT, Vista ES, Dedeke AB, Thompson DM, Stewart S, et al.Influenza vaccination responses in human systemic lupus erythematosus: impact of clinical and demographic features. Arthritis Rheum2011;63:2396406.
  • 22
    Mathian A, Devilliers H, Krivine A, Costedoat-Chalumeau N, Haroche J, Boutin-Le Thi Huong D, et al.Factors influencing the efficacy of two injections of a pandemic 2009 influenza A (H1N1) nonadjuvanted vaccine in systemic lupus erythematosus. Arthritis Rheum2011;63:350211.
  • 23
    Campos LM, Kiss MH, Scheinberg MA, Mangueira CL, Silva CA.Antinucleosome antibodies in patients with juvenile systemic lupus erythematosus. Lupus2006;15:496500.
  • 24
    Wallin L, Quintilio W, Locatelli F, Cassel A, Silva MB, Skare TL.Safety and efficiency of influenza vaccination in systemic lupus erythematosus patients. Acta Reumatol Port2009;34:498502.
  • 25
    Holvast A, van Assen S, de Haan A, Huckriede A, Benne CA, Westra J, et al.Studies of cell-mediated immune responses to influenza vaccination in systemic lupus erythematosus. Arthritis Rheum2009;60:243847.
  • 26
    Herron A, Dettleff G, Hixon B, Brandwin L, Ortbals D, Hornick R, et al.Influenza vaccination in patients with rheumatic diseases: safety and efficacy. JAMA1979;242:536.
  • 27
    Gabay C, Bel M, Combescure C, Ribi C, Meier S, Posfay-Barbe K, et al, for the H1N1 Study Group.Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. Arthritis Rheum2011;63:148696.
  • 28
    Elkayam O, Amir S, Mendelson E, Schwaber M, Grotto I, Wollman J, et al.Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases. Arthritis Care Res (Hoboken)2011;63:10627.
  • 29
    Borba EF, Saad CG, Pasoto SG, Calich AL, Aikawa NE, Ribeiro AC, et al. Antimalarials: a window of opportunity to improve the influenza A/H1N1 vaccine response in lupus patients under immunosuppressive agents. Rheumatology (Oxford). In press.
  • 30
    Urowitz MB, Anton A, Ibanez D, Gladman DD.Autoantibody response to adjuvant and nonadjuvant H1N1 vaccination in systemic lupus erythematosus. Arthritis Care Res (Hoboken)2011;63:151720.
  • 31
    Lu CC, Wang YC, Lai JH, Lee TS, Lin HT, Chang DM.A/H1N1 influenza vaccination in patients with systemic lupus erythematosus: safety and immunity. Vaccine2011;29:44450.
  • 32
    EMA, European Committee for Proprietary Medicinal Products. Guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application. London: European Agency for the Evaluation of Medicinal Products; 2004. URL:
  • 33
    US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for industry: clinical data needed to support the licensure of pandemic influenza vaccines. 2007. URL:
  • 34
    EMA, European Committee for Proprietary Medicinal Products. Note for guidance on harmonisation of requirements for influenza vaccines. London: European Medicines Agency; 1996. URL: _library/Scientific_guideline/2009/09/WC500003945.pdf.
  • 35
    Soonawala D, Rimmelzwaan GF, Gelinck LB, Visser LG, Kroon FP.Response to 2009 pandemic influenza A (H1N1) vaccine in HIV-infected patients and the influence of prior seasonal influenza vaccination. PLoS One2011;6:16496.